Header Logo

Connection

Michael Horberg to RNA, Viral

Back to Details
This is a "connection" page, showing publications Michael Horberg has written about RNA, Viral.
Michael Horberg
Connection Strength
1.286
RNA, Viral
  1. The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD. J Acquir Immune Defic Syndr. 2024 Nov 01; 97(3):232-241.
    View in: PubMed
    Score: 0.243
  2. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
    View in: PubMed
    Score: 0.147
  3. Hepatitis C screening trends in a large integrated health system. Am J Med. 2014 May; 127(5):398-405.
    View in: PubMed
    Score: 0.115
  4. Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. 2012 May; 26(5):253-5.
    View in: PubMed
    Score: 0.101
  5. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
    View in: PubMed
    Score: 0.084
  6. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.080
  7. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
    View in: PubMed
    Score: 0.077
  8. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
    View in: PubMed
    Score: 0.076
  9. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):531-9.
    View in: PubMed
    Score: 0.072
  10. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr. 2006 Sep; 43(1):56-9.
    View in: PubMed
    Score: 0.069
  11. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
    View in: PubMed
    Score: 0.047
  12. Changes in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data. AIDS Behav. 2020 Jun; 24(6):1784-1792.
    View in: PubMed
    Score: 0.045
  13. Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015 Dec 01; 182(11):952-60.
    View in: PubMed
    Score: 0.033
  14. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):149-63.
    View in: PubMed
    Score: 0.027
  15. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012 Sep 04; 157(5):325-35.
    View in: PubMed
    Score: 0.026
  16. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35.
    View in: PubMed
    Score: 0.024
  17. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26.
    View in: PubMed
    Score: 0.021

© 2024 Kaiser Permanente